Wayne Brandes, DO, American Institutes for Research, 10720 Columbia Pike, Suite 500, Silver Spring, MD 20901, 301-592-2163, kcyr@air.org

This session will provide an introduction to opioid addiction treatment under the new clinical and regulatory model established by the Drug Addiction Treatment Act of 2000 (DATA 2000). DATA 2000 allows qualified physicians, for the first time in more than 90 years, to dispense or prescribe approved Schedule III, IV, and V opioid medications for the treatment of opioid addiction outside of the context of the traditional Opioid Treatment Program setting. On October 8, 2002, two new formulations of the Schedule III opioid partial agonist medication buprenorphine (Suboxone® and Subutex®) became the first pharmaceuticals to receive FDA approval for use under the DATA 2000 paradigm. This new treatment paradigm promises to bring opioid addiction therapy into the mainstream of medical care, thereby greatly increasing utilization and access to care and helping to close the “treatment gap.”

Learning Objectives:

Understand the new office-based opioid addiction treatment paradigm that was enabled by the Drug Addiction Treatment Act of 2000 (DATA 200
• and the FDA approval of buprenorphine (Subutex and Suboxone). Learn pharmacologic and non-pharmacologic aspects of office-based opioid addiction treatment and how counseling professionals can partner with physicians and other treatment team members to provide maximally effective therapy for their patients under this new treatment model. Identify the resources available for further learning about non-pharmacologic therapies for opioid addiction, the DATA 2000 regulatory paradigm, and office-based opioid addiction treatment.

Related Web page: buprenorphine.samhsa.gov

Presenting author's disclosure statement:
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.